文献速递临床试验与 GCP

强化胰岛素治疗与血浆置换治疗高甘油三酯血症性急性胰腺炎的对比(Bi-TPAI试验):随机对照试验研究方案

Intensive insulin therapy versus plasmapheresis in the management of hypertriglyceridemia-induced acute pancreatitis (Bi-TPAI trial): study protocol for a randomized controlled trial.
PubMed 文献 · Trials · 2019-06-18

Bi-TPAI试验是一项多中心、平行组、随机、对照、非劣效性试验,计划纳入中国17家大型三级医院的220例早期高甘油三酯血症性急性胰腺炎(HTG-AP)患者,比较强化胰岛素治疗与血浆置换。主要终点为甘油三酯(TG)降至500 mg/dl所需时间;次要终点包括ICU及住院时间、28天死亡率、HTG-AP严重程度、低血糖发生率、并发症及成本效果。试验旨在证明强化胰岛素治疗不劣于血浆置换。

要点

  • 强化胰岛素组静脉持续输注常规人胰岛素,起始速率0.1单位/kg·h,最高0.3单位/kg·h。
  • 血浆置换组接受标准容量血浆置换。
  • 主要终点为TG降至500 mg/dl所需时间,次要终点含28天死亡率、低血糖及成本效果。

核心结论

  • Bi-TPAI试验将证明强化胰岛素治疗不劣于血浆置换。
  • 强化胰岛素治疗应成为HTG-AP有效、安全、可及且更便宜的降TG治疗。

研究设计与样本

  • 多中心、平行组、随机、对照、非劣效性试验。
  • 计划纳入中国17家大型三级医院的220例早期HTG-AP患者。

主要发现

  • 强化胰岛素组静脉持续输注常规人胰岛素,速率0.1单位/kg·h至最高0.3单位/kg·h。
  • 血浆置换组接受标准容量血浆置换。
  • 主要终点为TG降至500 mg/dl所需时间。
  • 次要终点包括ICU及住院时间、28天死亡率、HTG-AP严重程度、低血糖发生率、HTG-AP并发症及成本效果。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: It is widely agreed that triglyceride (TG)-lowering therapy is imperative in early hypertriglyceridemia-induced acute pancreatitis (HTG-AP). Intravenous insulin with or without heparin, and plasmapheresis are available regimens. However, there is no consensus on first-line therapy. METHODS/DESIGN: The Bi-TPAI trial is a multicenter, parallel group, randomized, controlled, non-inferiority trial in patients with early HTG-AP. The Bi-TPAI trial will include 220 patients with HTG-AP from 17 large tertiary hospitals in China. Patients assigned to the intensive insulin group will be administered an intravenous continuous infusion of regular human insulin at a rate of 0.1 units/kg·h and up to 0.3 units/kg·h. Patients allocated to the plasmapheresis group will receive standard-volume plasmapheresis. The primary endpoint is the time it takes for the TG level to reduce to 500 mg/dl. The secondary endpoints are ICU and hospital lengths of stay, 28-day mortality, severity of HTG-AP, incidence of hypoglycemia, HTG-AP complications, and cost-effectiveness. DISCUSSION: The Bi-TPAI trial will prove that intensive insulin therapy is non-inferior to plasmapheresis. Intensive insulin therapy should be an effective, safe, available, and cheaper triglyceride-lowering therapy for hypertriglyceridemia-induced acute pancreatitis. TRIAL REGISTRATION: ClinicalTrials.gov, NCT03342807 . Registered on 5 Nov 2017.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Song X, Shi D, Cui Q, et al. Intensive insulin therapy versus plasmapheresis in the management of hypertriglyceridemia-induced acute pancreatitis (Bi-TPAI trial): study protocol for a randomized controlled trial. Trials. 2019. PMID: 31215460. doi:10.1186/s13063-019-3498-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。